Phase Space AI

Valuation and Trade

10x Genomics [TXG]

10x Genomics [TXG] — Valuation, Criteria Scorecard, Trade Construction & Catalysts

Phase Space Research | original 2026-07-27 · methodology update 2026-07-29 | framework v1.7.0 (Criteria ruleset, references/criteria.md 2026-07-29) | Price at update $47.02 (2026-07-28 close) | EV $5.49bn

This memo no longer issues a position verdict. It scores Criteria and produces two valuation outputs. Sections written under the retired "Gate / E[R] vs cash hurdle" ruleset are marked SUPERSEDED where their conclusions no longer stand. Their evidence is retained deliberately — and TXG's earnings-quality findings (§0.7) are untouched by the valuation correction.

---

0. Methodology update — 2026-07-29. What changed, and why the answer did NOT move

0.1 The old conclusion, and the defect that was present in it

The 2026-07-27 memo concluded "WATCHLIST — no position; probability-weighted value $22.38 against a $45.92 spot; scenario-weighted E[R] −51.3% against a +4.7% cash hurdle, a −56.0pp shortfall." The same two defects that corrupted the NTRA, GH and TWST conclusions were present here too:

1. The exit multiple (base 5.5x sales) was anchored on Qiagen and Illumina — 3–4% and 1% growers — inside a diagnostics/tools set spanning 1.0–7.5% growth.
2. The sensitivity ran over scenario probabilities, and §3.2 again established that no probability weighting could change the answer.

But TXG is the case where fixing the defect does not rescue the name, and that is the most important thing in this update. A growth-matched anchor helps a company whose growth is high. TXG's demonstrated three-year revenue CAGR is 7.6% — and negative on the memo's own ex-settlement basis. Growth-matching a 7.6% grower returns a low multiple, correctly. The corrected method makes TXG look worse, not better, and it fails across the entire sensitivity band.

0.2 Inputs — the scan record was INDETERMINATE and had to be completed

reports/scan/TXG_analysis.json returned "status": "INDETERMINATE", note: "no share count" — so it carries no EV, no exit multiple and no required CAGR. Per the Criteria a missing input is INDETERMINATE and never FAIL (item D1). The missing field was retrieved from EDGAR rather than the name being dropped:

Resulting EV: $5,492m = 8.60x TTM revenue.

0.3 The implied-path test (reverse DCF) — the Valuation Criteria

assets/reverse_dcf.py, solving for revenue CAGR. Held fixed: terminal EBIT margin 20.0%, exit multiple 22.7x EBIT, WACC 10.0%, horizon 5 years, EV $5,492m, revenue base $638.8m.

What the price requires: a 25.0% five-year revenue CAGR.

What 10x has demonstrated: 7.6% over three years — and −2.3% on the memo's own ex-settlement LTM basis.

MARGIN = demonstrated − required = −17.4 percentage points. Valuation Criteria: FAIL, decisively.

The exit multiple and its compression, as a number. 22.7x EBIT at a 20% terminal margin is 4.54x exit-year sales, against 8.60x trading today — a −47.2% implied compression. Basis GROWTH_MATCHED, n=21, drawn from comparators growing 4.2% to 11.4% and bracketing TXG's 7.6% on both sides: IQV (4.2%, 24.4x), BDX (5.0%, 25.3x), MDT (5.2%, 20.0x), LH (5.6%, 22.1x), ZBH (5.9%, 22.6x), CAH (7.1%, 22.1x), COO (7.3%, 22.7x), STE (9.4%, 22.5x), CRM (9.8%, 21.5x), UNH (11.4%, 22.7x) among others. This is a well-identified anchor — and notably, it is a higher multiple than the old memo's 5.5x sales implied. The failure is not an anchoring artifact.

0.4 Sensitivity — over the exit multiple, never over scenario probabilities

This is the finding. TXG fails at every point of the exit-multiple sensitivity, including at 1.5× the growth-matched anchor. The break-even exit multiple at the demonstrated 7.6% CAGR is 48.0x EBIT / 9.60x exit-year sales — 2.1× the anchor, and above every comparator in the qualifying set bar one outlier. Unlike NTRA, GH and TWST, TXG's negative conclusion is not an artifact of the anchoring defect and does not move when the defect is fixed. That distinction is the entire reason the sensitivity is now run on this parameter.

Second sensitivity, and it is damning. Holding 7.6% growth and 22.7x, the break-even terminal EBIT margin is 42.3%. No diagnostics or life-science-tools company earns a 42% EBIT margin; Illumina's best year was in the mid-20s. The 20% flat terminal margin is already generous to TXG, and the price needs more than double it.

0.5 Caveat on the terminal margin — here it cuts in the company's favour

The flat 20% the scan applies to every name is an assumption, not a measurement. For TXG it is a generous one: FY2025 GAAP operating margin was −9.5%, and that figure itself includes ~$94m of non-recurring litigation income (§0.7). Using a lower, more defensible terminal margin would make the required CAGR higher still and the −17.4pp margin worse. The FAIL is robust to this parameter in the direction that matters.

0.6 The 12-month target

• Revenue base: TTM $638.8m grown at the Street's implied FY2026 growth (−4.5%: consensus FY2026E $614.06m, 15 analysts, cached 2026-07-27, vs FY2025 actual $642.8m) → NTM $610m. The Street's own base case is revenue declining. Disclosed gap: FY2027E consensus is not on file and the Alpha Vantage quota (25/day, shared) was exhausted on 2026-07-29; per the Consensus Criteria that leaves the field blank and blocks nothing.
• Multiple anchor — 10x's own EV/Sales history, 2022-07-01 to 2026-07-28 (1,021 trading days, EV rebuilt daily from then-current shares and then-reported TTM revenue): today 8.60x = the 79th percentile of the four-year range (min 0.52x, median 4.17x, upper quartile 7.94x, max 12.57x). Against the trailing twelve months alone, 8.60x is the 99th percentile (1y median 2.87x) — the stock has roughly tripled in twelve months on an essentially flat revenue line.

Note what makes TXG different from the other three: even the "multiple held flat" case is negative (−4.1%), because the Street's own revenue base is shrinking. For NTRA, GH and TWST, holding the multiple produces +19%, +33% and +16% respectively — the revenue growth carries the price. Here there is no revenue growth to carry it. Base is the four-year upper quartile rather than either median, deliberately the most generous of the three anchors that is still drawn from the name's own history.

Named 12-month product-cycle events feeding it (dated in §4): Q2-2026 earnings 6 August 2026 (first Atera order commentary); the first Atera shipping quarter (Q4-2026, reported ~Feb 2027) with FY2027 guidance — "the first guide that cannot lean on settlements"; the Parse PTAB appeal at the Federal Circuit.

Sanity band. Street average target $41.54 (−11.7% to spot) — the Street itself is below spot, and its average sits within $0.43 of this base target. The external healthcare specialist's book (snapshot 2026-07-28) carries TXG long at a +13% expected return on a thesis of "AI models drive acceleration in single cell / spatial" — an acceleration thesis, which is precisely the parameter the implied-path test measures and finds absent in the record so far. The divergence is a disagreement about future acceleration, not about arithmetic, and it is reported rather than tuned away.

0.7 Earnings quality — UNAFFECTED by the valuation correction, and preserved in full

The anchoring defect had nothing to do with these findings and fixing it does not soften them.

1. FY2025 revenue of $642.8m includes ~$94m of non-recurring litigation settlement income. Reported FY2025 growth was +5.2% against FY2024's $610.8m. Ex-settlement, LTM revenue was $597m and growth was −2.3% (the memo's own comps table, §1.3). The "FY2025 turnaround" is litigation income, not commercial recovery.
2. The same settlements flatter the operating line: FY2025 GAAP operating margin improved to −9.5% from −31.9%.
3. The underlying commercial series are the ones to watch: instrument revenue −54% in two years and −24% y/y in Q1-2026; Single Cell consumables −13.6%; NIH S10 instrumentation grants −5% in dollars and −17% in count.
4. The Q4-2026 print (~Feb 2027) is the first guide that cannot lean on settlements, which is why it is the most informative dated event on the calendar.

These findings are scored under Quality Criteria (accruals / earnings-quality limb), not under valuation, and they stand independently of any exit multiple.

0.8 Criteria scorecard (Gates retired 2026-07-29)

Archetype: INFLECTION by operating margin (−9.5% FY2025), though the growth profile is not an inflection profile — flagged, because the archetype declaration is calibration item B23 and TXG sits awkwardly across it.

0.9 What moved, in one line

Old: worth $22.38 against a $45.92 spot; E[R] −51.3%; a −56.0pp shortfall; WATCHLIST. New: the price requires a 25.0% five-year revenue CAGR against 7.6% demonstrated — a −17.4pp margin, FAIL — and a 12-month base target of $41.97 (−10.7%), within $0.43 of the Street's own average target. Why it barely moved: TXG is the control case. The anchoring fix raised its exit multiple (22.7x EBIT ≈ 4.5x sales versus the old memo's 5.5x sales, on a corrected and larger revenue base) and the name still fails, at every point of the sensitivity, by a wide margin. The old conclusion was reached by a defective route; the new one is reached by a sound route and lands in the same place. Correcting the anchoring defect does not make a 7.6% grower at 8.6x sales attractive, and this memo does not pretend otherwise.

---

1. Valuation

1.1 DCF — reported, and moderately down-weighted (but usable, unlike GH's)

Why this DCF is more usable than GH's. The GH memo correctly down-weighted a DCF whose terminal value was 98.8% of enterprise value. TXG's is 51.6% — high, but roughly half of the value comes from explicitly forecast cash flows, because TXG's unlevered FCF turns positive in FY2028E rather than FY2030+. The DCF is therefore a real input here, not an artifact. It is still not the primary tool: a 15.44% CAPM discount rate on a beta of 2.15 is punishing and contestable, so the grid below runs from 10.0% to 20.0%.

Sensitivity — value per share. Every cell is far below spot:

1.2 Scenario framework — this carries the weight

Valued on FY2030E revenue at an anchored exit multiple, discounted back 4.5 years at 15.44%.

SUPERSEDED (2026-07-29). Probability-weighted value $22.38 · Scenario-weighted expected return −51.3% · versus a 4.7% cash hurdle, a shortfall of −56.0 percentage points. This output is retired — the cash hurdle no longer exists and the exit multiples below (3.0x / 5.5x / 8.5x) were anchored on Qiagen and Illumina, 1–4% growers. The revenue build is kept; its valuation conclusion is not. Replacement: §0.3. Unlike the other three names in this batch, the corrected method reaches the same negative conclusion by a sound route.

The single most important line in this memo: at a sector-typical 10% discount rate, the Bull case is worth $46.64 and the stock trades at $45.92. The market is paying, in full, for the bull case discounted at a benign rate. Every other cell in the table is below spot.

Where the exit multiples come from — anchored, not picked. Bear 3.0x ≈ Bruker (3.4x on 2% growth, 50% gross margin). Base 5.5x sits between Qiagen (4.7x, 3% growth, 66% GM) and Illumina (6.8x, 1% growth, 66% GM) — the two closest analogues for a high-margin, low-growth tools franchise. Bull 8.5x is a full re-rating above today's 7.5x peer median, granted on Atera succeeding.

Robustness. Holding base FY2030E revenue at $832m: $21.26 at 5.5x · $27.00 at 7.0x · $29.00 at 7.5x (today's peer median) · $32.90 at 8.5x. Even at today's peer median applied to a year five out, the stock is 37% overvalued. The conclusion does not depend on the multiple choice, which is what makes it usable.

1.3 Comparables

TXG has the highest gross margin in the set and, ex-settlements, the lowest growth. It trades above the peer median on both counts being unfavourable.

1.4 Consensus bridge (required)

Decomposing the disagreement — numbers or multiple? Entirely the multiple, and provably so. House and Street are 0.5% apart on FY2026E revenue — inside forecast noise, and well inside the sub-5% threshold that the ISRG precedent established as unable to carry a thesis. The entire $19 gap between the Street's $41.54 and the house's $22.38 comes from the exit multiple applied to a broadly agreed revenue path. The Street is implicitly capitalising FY2030E revenue at roughly 11x; the house uses 5.5x, anchored on Qiagen and Illumina.

And the most striking fact about consensus is not the level — it is the direction of travel. The four most recent target changes on file:

Three analysts raised their price targets by 74–90% in eight days while explicitly maintaining Hold ratings. That is not a research process leading a stock; it is a research process marking to market behind one. And the resulting average target of $41.54 still sits 9.5% BELOW the current price. The Street does not support this price either — it has simply stopped arguing with it.

---

2. Factor & Anomaly Scorecard

Synthesis. The anomaly factors and the fundamental view split, and they split in the direction that kills any short. Momentum, trend, 52-week-high proximity and gross profitability all support ownership; the margin_vs_own_history check explicitly clears TXG of the peak-cycle charge. The only negative factors are the revision direction (FY2026 revenue being marked down) and the multiple. Shorting a top-decile-momentum, below-median-margin, debt-free franchise is close to the textbook profile of a bad short.

2.1 A correction to the premise this batch was set up with — and it is important

The brief stated that TXG and TWST "arrive cheap and beaten-up rather than extended," and that they would therefore test calibration item B1 (does Gate 6 penalise buying weakness?).

That premise is factually wrong, and the data is unambiguous:

Neither name is beaten-up. Both are among the most extended names in the liquid US market. The GH memo reached the same conclusion from the other direction (GH, TWST and TXG were all top-decile momentum names, invisible to the screen only because a stage_c_cap: 75 truncation pushed the effective threshold to +405%).

Consequence for the experiment: calibration item B1 IS NOT TESTED BY THIS BATCH. Gate 6 is a tailwind on the long side for both names. It does not bind, it cannot bind, and no evidence about whether Gate 6 wrongly penalises buying weakness can be extracted from either memo. That is the honest report, and the finding is recorded in §7.

---

3. Trade Construction — the four conclusions, kept separate

1. Fundamental conclusion — MIXED, tilted negative. Products-and-services revenue has fallen for two consecutive years and is 3.6% below FY2023. Instruments −54% in two years. Consumable Single Cell −13.6%. Against that: gross margin is recovering off a trough, opex fell 9% genuinely, the balance sheet is debt-free with $540m of cash, and Atera is a real product from the category leader.
2. Expectations conclusion — FULLY DISCOUNTED, AND THEN SOME. 16 analysts at Buy; consensus revenue within 0.5% of the house build; the stock +225% in twelve months; and the Street's average target is 9.5% BELOW spot after three analysts raised targets 74–90% in eight days while keeping Hold ratings. There is no expectations gap in the house's favour. There is a negative one.
3. Valuation conclusion — RESTATED 2026-07-29, and unchanged in direction. (Was: "NEGATIVE — probability-weighted value $22.38 vs $45.92.") On the implied-path test the price requires a 25.0% five-year revenue CAGR against 7.6% demonstrated: a −17.4pp margin, Valuation Criteria FAIL, holding at every point from 0.6× to 1.5× of the growth-matched exit multiple. 12-month base target $41.97 (−10.7%). See §0.3–§0.6.
4. Portfolio conclusion — REMOVED. (Was: "NO POSITION.") This memo issues no position verdict. It scores Criteria (§0.8) and produces two valuation outputs. The short-side observations are retained under Short Mechanism Criteria, which scores PARTIAL (deceleration evidenced; margin runway not exhausted).

3.1 Criteria-by-Criteria (evidence retained; verdicts restated in §0.8)

"Gates" were retired on 2026-07-29. Below is the original gate block with names mapped forward. The reasoning column is unaltered — it is the record. Where a verdict changed, §0.8 is authoritative.

RESTATED 2026-07-29. (Original: "THE BINDING GATE IS GATE 4 (expected return), with Gate 2 failing independently on both branches.")

The memo does not name a binding gate any more, because it does not issue a verdict. Of the BINDING Criteria the strategy consumes, Valuation FAILS by 17.4pp and Quality FAILS on the revenue-growth limb (7.6% 3y CAGR, acceleration below zero, ex-settlement LTM growth −2.3%). Momentum Criteria is MEASURED and blocks nothing — that part of the original note was already correct and is retained.

3.2 E[R] range and flip point (SUPERSEDED 2026-07-29 — this is the defect, preserved)

Read this as the exhibit, not the analysis. It ranges over scenario probabilities and concludes that no probability assignment can change the answer — which is the proof that the sensitivity was run on a parameter that could not move the result. The replacement, a sensitivity over the exit multiple with a break-even multiple stated, is §0.4. The conclusions below, including the $21.38 "entry", do not stand.

E[R] RANGE: −44.4% to −65.3%. Cash hurdle: +4.7%.

The hurdle sits FAR OUTSIDE the range — it is not close to any part of it. Even at a 0% bear weight — assuming the bear case is impossible — expected return is −44.4%, still 49 percentage points below the hurdle.

FLIP POINT on bear weight: UNREACHABLE. There is no probability weighting of these three scenarios that produces a passing expected return. Solving for it returns a bear weight of −216%, i.e. outside [0,1]. The decision does not turn on the scenario probabilities, which is precisely the criticism calibration item B7 levels at Gate 4 — and here that criticism does not apply.

FLIP POINT on price: $21.38. At $21.38 (−53.4% from spot) the probability-weighted expected return equals the 4.7% cash hurdle. That is the entry level, and it is the actionable output.

3.3 Gate 5 — implementation feasibility, assessed early

Liquidity Criteria verdict (restated 2026-07-29): PASS on equity; FAIL on options — too wide and too rich to express anything efficiently; a vehicle that cannot be filled is not a vehicle. (Borrow and short interest are no longer part of this Criteria on a long-only book; they sit under Short Mechanism Criteria.) Original text follows.

Gate 5 verdict: PASS for outright equity; the options market is too wide and too rich to express anything efficiently. Note this is the opposite of the pattern flagged in calibration item S2 — Gate 5 is not the binding constraint on TXG.

3.4 Analysis summary — no position verdict is issued

POSITION VERDICT: NONE. This memo does not output Long / Short / Watchlist / Avoid.
                  It outputs an analysis. Whether it justifies a position belongs to a book.

VALUATION CRITERIA (implied path, 5y):  price requires 25.0% revenue CAGR
                                        demonstrated 7.6% (3y), -2.3% ex-settlement LTM
                                        MARGIN -17.4pp   FAIL - AND ROBUST
   exit multiple 22.7x EBIT = 4.54x exit sales, basis GROWTH_MATCHED (n=21, comparators 4.2%-11.4%
   growth, bracketing TXG on both sides) - computed here because the scan record was INDETERMINATE
   for an absent share count, which is an absent input and never a FAIL (item D1)
   implied compression from 8.60x trading today: -47.2%
   FAILS AT EVERY POINT FROM 0.6x TO 1.5x OF THE ANCHOR. Break-even exit multiple 48.0x EBIT
   (2.1x the anchor); break-even terminal EBIT margin 42.3% - no company in the sector earns that.
   THIS IS THE CONTROL CASE: fixing the anchoring defect does not change the answer.
12-MONTH TARGET: $41.97 base (-10.7% to $47.02 spot); low $17.85 (-62.0%); high $45.11 (-4.1%)
                 multiple anchored on TXG's OWN EV/Sales history (8.60x = 79th pctile of 4y,
                 99th pctile of 1y); revenue base NTM $610m off a Street FY2026E that DECLINES 4.5%
                 Even the multiple-held case is negative - there is no revenue growth to carry it.
QUALITY CRITERIA (BINDING): FAIL - gross-margin limb PASSES at 69.1% (highest in the batch), but the
                 revenue-growth limb FAILS (7.6% 3y CAGR vs a ~18% bar, acceleration below zero) and
                 the operating-margin improvement contains ~$94m of non-recurring litigation income.
                 EARNINGS-QUALITY LIMB FLAGGED - UNAFFECTED by the valuation correction. See §0.7.
LIQUIDITY CRITERIA (BINDING): PASS on equity; FAIL on options (too wide, too rich)
MOMENTUM CRITERIA (MEASURED - ENTRY TIMING ONLY, NEVER SELECTION):
                 12-1 +153.5% (82.1st pctile), 6-1 +72.0% (80.2nd), 97.8% of the 52-week high,
                 RSI-14 72.2 - the only one of the four in overbought territory. Worst entry timing
                 of the batch, which is a statement about timing and about nothing else.
DOWNSIDE CRITERIA (MEASURED): the settlement stream ends and the FY2027 guide has to stand on
                 commercial revenue alone. Not a going-concern case: $539.8m net cash, no debt.
CATALYST / PEER SPREAD / CONSENSUS / SHORT MECHANISM: see §0.8
TIME HORIZON:    Q2-2026 earnings (6 Aug 2026), then the first Atera shipping quarter
                 (Q4-2026, reported ~Feb 2027) - the first guide that cannot lean on settlements
CONSENSUS:       Street Buy, 16 analysts, average target $41.54 - 11.7% BELOW spot, and within
                 $0.43 of this memo's base target. External reference book: long TXG at +13% on an
                 acceleration thesis - the exact parameter the implied-path test finds absent.
WHAT WOULD CHANGE THE VALUATION CRITERIA VERDICT (not a position trigger):
- Total instrument revenue above $25m in any quarter of 2027 (vs $11.3m in Q1-2026)
- FY2027 revenue guidance above $720m
- Spatial consumables re-accelerating above +30% y/y (vs +18.9% in FY2025)
- A definitive Illumina litigation outcome in either direction
INVALIDATION TRIGGERS:
- Total instrument revenue exceeds $25m in any quarter of 2027 (vs $11.3m in Q1-2026) — placement cycle restarting
- FY2027 revenue guidance above $720m (vs the house base of $691m)
- Spatial consumables re-accelerating above +30% y/y (vs +18.9% in FY2025)
- A definitive Illumina litigation outcome in either direction

This is the "expensive but not a short" case and it is named as such. The trade-construction reference warns that this trap recurs; TXG is a textbook instance. (Restated 2026-07-29: skepticism about a multiple is no longer the load-bearing argument here. The implied-path test converts it into a measurement — the price requires 25.0% revenue growth from a business demonstrating 7.6% — which fails at every exit multiple from 0.6× to 1.5× of a growth-matched anchor. That is evidence, not skepticism.) I am skeptical of an 8.6x multiple on a business that has not grown in three years. Scored honestly, skepticism is not Gate 1 or Gate 2 evidence, and it is not dressed up here as if it were.

3.5 Vehicles priced, and why each was rejected

Alpaca options data pulled live, 2026-07-27.

Variance risk premium check (mandatory before any naked premium). ATM implied volatility across the four expirations runs 87–107% against 68.6% realised. Implied is ~1.4x realised across the entire surface. There is no expiration at which the house expected move exceeds what the options market has already priced. Per references/alpaca-options.md, naked long premium is therefore ruled out, and the defined-risk spreads above are ruled out on their own geometry.

IV crush would apply to any structure: TXG reports 6 August 2026, ten days out, and August IV will collapse immediately afterward regardless of direction. Flagged, though moot given no position.

3.6 Portfolio-book context (portfolio_book.json contract executed)

Book is 100% cash; config: 5% single-name max, 4.7% cash hurdle, −2%-of-book position hard stop, 25% sector concentration cap, 0.60 pairwise-correlation disclosure threshold.

• Capital competition — SUPERSEDED. (Was: "FAILS decisively. Net E[R] −51.3% vs a risk-free 4.7%.") The cash hurdle has been retired from the framework; capital competition is slot competition inside the strategy and the memo does not run it. On the Criteria the memo does score, the Valuation Criteria fails by 17.4pp and the Quality Criteria fails on the revenue-growth limb.
• Correlation: TXG's mean correlation to the ten-name AI-infrastructure cluster is +0.211 (per the GH memo's cross-check, same date). No limit breached. TXG and TWST correlate meaningfully to each other — if both ever convert, they would count as one life-science-tools cluster against the 25% sector cap.
• Sector concentration: a first life-science-tools position would open a valuable new cluster in a book that is otherwise entirely one factor. That is not a reason to buy at this price.
• Write-back: Watchlist entry with two-sided conversion triggers, in PENDING_book_and_ledger_updates.json.

3.7 Joint probability the conversion triggers fire together (v1.4.2, item C6)

→ LONG conversion. Two independent paths, OR'd:

These two paths are close to mutually exclusive (the price falling 53% while Atera succeeds is contradictory), so P(either fires) ≈ 40–45%, and P(both fire together) ≈ 2%.

The relevant number under item C6 is P(the long conversion becomes live) ≈ 40–45% over twelve months. That is comfortably above the ~10% threshold, so this Watchlist is REAL, not a no-position wearing a watchlist costume.

→ SHORT conversion. Three conditions, all required (AND'd):

JOINT probability all three fire together: ~2.1%. These are positively correlated (a guidance miss makes a trend break likelier), so a generous correlated estimate is ~5%.

That is below the ~10% threshold. The SHORT conversion on TXG is honestly classified as NO POSITION wearing a watchlist costume, and it is recorded as such rather than left on the book as a live trigger.

---

4. Catalyst Calendar

---

5. What would make me wrong

1. Atera could be Xenium again. TXG's own history is the strongest argument against my base case: Xenium took spatial consumables from $59.2m to $144.0m in two years. I have given that a 25% weight; a 40% weight moves the probability-weighted value to ~$26 — still far below spot, but the direction is real.
2. The AI-dataset partnerships may be worth more than the instruments, and I cannot price them. Bioptimus / STELA, Cancer Research Institute, PharosAI. If biological foundation models require proprietary spatial data at scale, TXG owns the generation layer for it. This is genuinely unpriceable and I have given it zero value.
3. Margins are below their own median, not above it. The 0.90 margin_vs_own_history reading is a real argument that the earnings base is depressed rather than peaked — and a mean-reverting margin model would be considerably more generous than mine.
4. The exit multiple is doing all the work. At ~11x FY2030E EV/Sales — roughly where the market is — the stock is fairly valued. My case that 5.5x is right rests on Qiagen and Illumina, which are anchors, not laws.
5. Takeout. A strategic bid at a premium to $45.92 would make all of this academic.

---

6. Feedback for the screener (idea-screener)

TXG was not momentum-selected for this batch, on the stated belief that it was a beaten-up value name. It is a top-decile momentum name, 102.8% above its 200-day moving average. This confirms and extends the GH memo's finding that the stage_c_cap: 75 truncation is hiding names that clear the stated top-8% threshold. The cap, not the threshold, is the binding constraint on what reaches underwriting.

---

7. Calibration Watch entries generated by this memo

These are logged, not acted on. No gate has been loosened.

---

Prepared by Phase Space Research, 2026-07-27. Options quotes, Greeks and IV: Alpaca (live, 2026-07-27). Price and volatility: Alpaca SIP. Consensus, targets, short interest and float: public aggregators (stockanalysis.com), 2026-07-27. Fundamentals: SEC EDGAR. Model: TXG_Financial_Model.xlsx, verified by reading back computed cells in Excel with all other workbooks closed — balance-sheet check is zero in all twelve columns.